I’m Mohammad Khajeh, currently pursuing my PhD at Boston University with a background in Chemical Engineering (BSc & MSc, Sharif University of Technology), one of the Middle East’s top engineering institutions.

As Head of R&D at NanoLipo Cancer Solutions, I lead the development and optimisation of our microfluidic platform for liposomal Doxorubicin, ensuring our formulations are reliable, reproducible, and ready for clinical translation.

My expertise spans microfluidic systems, nanoliposomal drug formulation, controlled-release mechanisms, and nanoparticle stability.

My focus is on bridging science and scalability, transforming NanoLipo’s innovations from proof-of-concept to clinically and commercially viable cancer therapies